{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T21:19:32Z","timestamp":1771017572424,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100008385","name":"Italian Cystic Fibrosis Research Foundation","doi-asserted-by":"crossref","award":["FFC#10\/2013"],"award-info":[{"award-number":["FFC#10\/2013"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007388","name":"Compagnia di San Paolo","doi-asserted-by":"publisher","award":["2013"],"award-info":[{"award-number":["2013"]}],"id":[{"id":"10.13039\/100007388","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Istituto Banco di Napoli \u2014 Fondazione","award":["Napoli_call2013_35"],"award-info":[{"award-number":["Napoli_call2013_35"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jconrel.2016.07.029","type":"journal-article","created":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T21:55:20Z","timestamp":1469051720000},"page":"80-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Development of inhalable hyaluronan\/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections"],"prefix":"10.1016","volume":"238","author":[{"given":"G.","family":"Costabile","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"d'Angelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"d'Emmanuele di Villa Bianca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Mitidieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Pompili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Del Porto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Visca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Miro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Quaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Imperi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Sorrentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0850-9533","authenticated-orcid":false,"given":"F.","family":"Ungaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2016.07.029_bb0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.idc.2015.10.012","article-title":"Antifungal agents: spectrum of activity, pharmacology, and clinical indications","volume":"30","author":"Nett","year":"2016","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0010","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.1073\/pnas.1222706110","article-title":"Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity","volume":"110","author":"Imperi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.jconrel.2016.07.029_bb0015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003495-200767030-00003","article-title":"The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections","volume":"67","author":"Driscoll","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2016.07.029_bb0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1513\/pats.200907-075AL","article-title":"Coping with Candida infections","volume":"7","author":"Evans","year":"2010","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0025","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/ppul.23302","article-title":"Association of chronic Candida albicans respiratory infection with a more severe lung disease in patients with cystic fibrosis","volume":"50","author":"Gileles-Hillel","year":"2015","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2014.10.009","article-title":"Clinical applications of pulmonary delivery of antibiotics","volume":"85","author":"Flume","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0035","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/QCO.0000000000000217","article-title":"Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis","volume":"28","author":"Langan","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0040","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/09031936.00090314","article-title":"Inhaled antibiotics: dry or wet?","volume":"44","author":"Tiddens","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0045","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/MCP.0000000000000109","article-title":"Dry powder inhalers in cystic fibrosis: same old drugs but different benefits?","volume":"20","author":"Uttley","year":"2014","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0050","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1183\/09059180.00001513","article-title":"Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis","volume":"22","author":"Uttley","year":"2013","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0055","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/jamp.2014.1155","article-title":"NanoCluster Itraconazole formulations provide a potential engineered drug particle approach to generate effective dry powder aerosols","volume":"28","author":"Pornputtapitak","year":"2015","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0060","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12281-010-0011-0","article-title":"Aerosolized delivery of antifungal agents","volume":"4","author":"Le","year":"2010","journal-title":"Curr. Fungal. Infect. Rep."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0065","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1021\/mp500808t","article-title":"Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection","volume":"12","author":"Arora","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0070","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ppul.22856","article-title":"Aerosolized liposomal amphotericin B: a potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients","volume":"49","author":"Kamalaporn","year":"2014","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0075","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2014.05.008","article-title":"Improving the efficacy of inhaled drugs in cystic fibrosis: challenges and emerging drug delivery strategies","volume":"75","author":"d'Angelo","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0080","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1517\/17425247.2015.1007949","article-title":"Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis\u2014where do we stand?","volume":"12","author":"Klinger-Strobel","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.03.017","article-title":"Formulation strategy and use of excipients in pulmonary drug delivery","volume":"392","author":"Pilcer","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0090","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v24.i4.10","article-title":"Spray-dried powders for pulmonary drug delivery","volume":"24","author":"Seville","year":"2007","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0095","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2005.09.004","article-title":"The influence of formulation components on the aerosolisation properties of spray-dried powders","volume":"110","author":"Rabbani","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.07.029_bb0100","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.powtec.2014.02.033","article-title":"Influence of excipients on spray-dried powders for inhalation","volume":"256","author":"Xu","year":"2014","journal-title":"Powder Technol."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0105","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ejpb.2008.06.013","article-title":"Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients","volume":"70","author":"Minne","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0110","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1021\/acs.molpharmaceut.5b00098","article-title":"Toward repositioning niclosamide for antivirulence therapy of Pseudomonas aeruginosa lung infections: development of inhalable formulations through nanosuspension technology","volume":"12","author":"Costabile","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0115","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejpb.2015.05.021","article-title":"Pulmonary delivery of pyrazinamide-loaded large porous particles","volume":"94","author":"Pham","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0120","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ijpharm.2015.10.019","article-title":"Minimal amounts of dipalmitoylphosphatidylcholine improve aerosol performance of spray-dried temocillin powders for inhalation","volume":"495","author":"Cuvelier","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0125","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1021\/acs.molpharmaceut.5b00046","article-title":"Pharmacokinetics of inhaled rifampicin porous particles for tuberculosis treatment: insight into rifampicin absorption from the lungs of Guinea pigs","volume":"12","author":"Garcia","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0130","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-23056-1_17","article-title":"Hyaluronic acid: perspectives in lung diseases","volume":"385\u2013401","author":"Allegra","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0135","first-page":"283","article-title":"Potential therapeutic applications of hyaluronan in the lung","volume":"2","author":"Cantor","year":"2007","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0140","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/1753465812458984","article-title":"Nebulized hypertonic saline containing hyaluronic acid improves tolerability in patients with cystic fibrosis and lung disease compared with nebulized hypertonic saline alone: a prospective, randomized, double-blind, controlled study","volume":"6","author":"Furnari","year":"2012","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0145","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/jamp.2012.1034","article-title":"Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial","volume":"27","author":"Ros","year":"2014","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0150","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijpharm.2004.09.001","article-title":"Hyaluronan-based microspheres as tools for drug delivery: a comparative study","volume":"288","author":"Esposito","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0155","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ijpharm.2013.04.016","article-title":"Formulation of pyrazinamide-loaded large porous particles for the pulmonary route: avoiding crystal growth using excipients","volume":"454","author":"Pham","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0160","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijpharm.2008.03.024","article-title":"A comparative study of a range of polymeric microspheres as potential carriers for the inhalation of proteins","volume":"358","author":"Sivadas","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0165","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0021-9258(18)65354-2","article-title":"Turbidimetric measurement of acid mucopolysaccharides and hyaluronidase activity","volume":"220","author":"Di","year":"1956","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0170","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2011.08.010","article-title":"Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers","volume":"157","author":"Ungaro","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.07.029_bb0175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.14227\/DT180311P15","article-title":"Simulated biological fluids with possible application in dissolution testing","volume":"18","author":"Marques","year":"2011","journal-title":"Dissolution Technologies"},{"key":"10.1016\/j.jconrel.2016.07.029_bb0180","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1128\/AAC.39.9.2051","article-title":"Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation","volume":"39","author":"Odds","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0185","series-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts \u2014 Approved Standard","author":"Clinical and Laboratory Standards Institute, M27-A3","year":"2008"},{"key":"10.1016\/j.jconrel.2016.07.029_bb0190","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/iai.28.3.899-908.1980","article-title":"Toxin A-deficient mutants of Pseudomonas aeruginosa PA103: isolation and characterization","volume":"28","author":"Ohman","year":"1980","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0195","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1128\/JB.187.15.5097-5107.2005","article-title":"Involvement of AlgQ in transcriptional regulation of pyoverdine genes in Pseudomonas aeruginosa PAO1","volume":"187","author":"Ambrosi","year":"2005","journal-title":"J. Bacteriol."},{"issue":"Suppl. 2","key":"10.1016\/j.jconrel.2016.07.029_bb0200","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jcf.2004.05.040","article-title":"Established cell lines used in cystic fibrosis research","volume":"3","author":"Gruenert","year":"2004","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0205","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1743-8977-6-14","article-title":"Comparative toxicity of 24 manufactured nanoparticles in human alveolar epithelial and macrophage cell lines","volume":"6","author":"Lanone","year":"2009","journal-title":"Part. Fibre Toxicol."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0210","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1021\/acsami.5b09023","article-title":"Amorphous calcium carbonate based-microparticles for peptide pulmonary delivery","volume":"8","author":"Tewes","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2016.07.029_bb0215","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jconrel.2014.04.055","article-title":"Pulmonary drug delivery by powder aerosols","volume":"193","author":"Yang","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.07.029_bb0220","article-title":"Inhaled mannitol for cystic fibrosis","volume":"10","author":"Nolan","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0225","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cis.2015.05.003","article-title":"Advantages and challenges of the spray-drying technology for the production of pure drug particles and drug-loaded polymeric carriers","volume":"223","author":"Sosnik","year":"2015","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0230","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2008.04.009","article-title":"Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis","volume":"129","author":"Hwang","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.07.029_bb0235","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.addr.2014.04.004","article-title":"Technological and practical challenges of dry powder inhalers and formulations","volume":"75","author":"Hoppentocht","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"Suppl. 2","key":"10.1016\/j.jconrel.2016.07.029_bb0240","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1089\/jamp.2010.0836","article-title":"The particle has landed\u2014characterizing the fate of inhaled pharmaceuticals","volume":"23","author":"Patton","year":"2010","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0245","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.addr.2014.05.017","article-title":"Delivery strategies for sustained drug release in the lungs","volume":"75","author":"Loira-Pastoriza","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0250","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions","volume":"46","author":"Vermes","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0255","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1128\/AAC.40.12.2907","article-title":"Efficacy of continuous flucytosine infusion against Candida lusitaniae in experimental hematogenous murine candidiasis","volume":"40","author":"Karyotakis","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2016.07.029_bb0260","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000069784","article-title":"An in vitro study on the active conversion of flucytosine to fluorouracil by microorganisms in the human intestinal microflora","volume":"49","author":"Vermes","year":"2003","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jconrel.2016.07.029_bb0265","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev-physiol-021115-105238","article-title":"The microbiome and the respiratory tract","volume":"78","author":"Dickson","year":"2016","journal-title":"Annu. Rev. Physiol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916304631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916304631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T14:00:59Z","timestamp":1656856859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365916304631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":53,"alternative-id":["S0168365916304631"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.07.029","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of inhalable hyaluronan\/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}